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Immunotherapeutic approaches can demonstrate some
antitumor benefit, but their efficacy is limited when they
are used as a single modality. We asked if a combinatory
approach activating both innate and adaptive immunity
would improve cancer immunotherapy. We have pre-
viously shown that an agonistic anti-CD40 monoclonal
antibody (anti-CD40) in combination with a toll-like
receptor 9 agonist, CpG, can activate macrophages in
mice, leading to tumor cell killing. Separately, we have
shown that a direct intratumoral injection of an immu-
nocytokine (IC) consisting of anti-GD2 antibody linked
to interleukin-2 can activate NK and T cells, resulting in
antitumor effects. We hypothesize that activation of
macrophages (with anti-CD40/CpG) and NK cells (with
IC) will increase tumor destruction and presentation of
tumor antigens, leading to T cell activation, which in
turn could be further augmented by anti-CTLA-4
antibody, resulting in tumor eradication and prevention
of tumor recurrence. Using the mouse GD2+ B78 mela-
noma model, we show that anti-CD40/CpG and IC/anti-
CTLA-4 synergistically induced regression of established
subcutaneous tumors, resulting in the cure of 50% of
mice and development of immunological memory
against B78 as well as wild type B16 tumors. While the
antitumor effect of anti-CD40/CpG was T cell indepen-
dent, the antitumor effect of IC/anti-CTLA-4 required
T cells. Anti-CD40/CpG treatment led to upregulation
of T cell activation markers in draining lymph nodes.
Finally, the combined treatment with anti-CD40/CpG
and IC/anti-CTLA-4 was effective against B16 lung
metastases. We suggest that a combination of anti-
CD40/CpG and IC/anti-CTLA-4 should be tested as a
clinically relevant novel treatment strategy.
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